Compare Eli Lilly And Co (LLY) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Wipro Limited — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Wipro Limited trades at $1.7 (market cap $16.22B). The key difference: Eli Lilly And Co is far larger — about 64.1× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (5.19%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Wipro Limited for 41 Days on average.
| LLY | WIT | |
|---|---|---|
Market Cap | $1.04T | $16.22B |
Volume | 3,064,878 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $1.28K | $3.06 |
52-Week Low | $799.57 | $1.61 |
Typical Hold Time | 93 Days | 41 Days |
Enterprise Value | $1.09T | $14.33B |
Dividend Yield | 0.59% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
WIT trades at $1.67, showing no change in the last session. The stock is in a bearish technical trend, with recent earnings missing expectations for multiple quarters. Financially, the company maintains solid profitability with a net margin of 13.92% and an ROE of 16.09% as of 2025. Recent news highlights strategic AI partnerships and productivity gains, but revenue growth remains subdued.
The outlook is cautious due to mixed analyst sentiment and earnings misses. Investment appeal lies in reasonable valuation multiples and strong cash flow generation. Key risks include competitive pressures in IT services and potential margin compression from wage inflation. Upside depends on successful execution of AI initiatives to drive future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
